<DOC>
	<DOCNO>NCT00747734</DOCNO>
	<brief_summary>This Phase I , first-in-human , open-label , dose-escalation study MNRP1685A administer IV infusion every 3 week patient locally advance metastatic solid tumor standard therapy either exist proven ineffective intolerable . This study conduct three study center United States .</brief_summary>
	<brief_title>A Study MNRP1685A Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age â‰¥ 18 year Incurable , locally advanced , metastatic solid malignancy progress , fail respond , least one prior regimen Evaluable measurable disease per RECIST ( certain circumstance , prostate ovarian cancer patient nonmeasurable disease ) Inadequate hematologic organ function Anticancer therapy within 4 week prior initiation study treatment Recent history current clinically significant gastrointestinal , cardiovascular pulmonary disorder Any condition require fulldose anticoagulant , warfarin , heparin , thrombolytic , filter inferior vena cava Active infection autoimmune disease Known human immunodeficiency virus ( HIV ) infection Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Neuropilin-1</keyword>
	<keyword>NRP1</keyword>
	<keyword>anti-NRP1</keyword>
	<keyword>anti-angiogenic</keyword>
</DOC>